- Home
- QNRX vs GLMD Comparison
QNRX vs GLMD Comparison
Compare QNRX & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QNRX
- GLMD
- Stock Information
- Founded
- QNRX 2018
- GLMD 2000
- Country
- QNRX United States
- GLMD Israel
- Employees
- QNRX N/A
- GLMD N/A
- Industry
- QNRX Medical/Dental Instruments
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- QNRX Health Care
- GLMD Health Care
- Exchange
- QNRX Nasdaq
- GLMD Nasdaq
- Market Cap
- QNRX 5.3M
- GLMD 4.6M
- IPO Year
- QNRX N/A
- GLMD 2014
- Fundamental
- Price
- QNRX $0.57
- GLMD $2.90
- Analyst Decision
- QNRX Strong Buy
- GLMD
- Analyst Count
- QNRX 1
- GLMD 0
- Target Price
- QNRX $4.00
- GLMD N/A
- AVG Volume (30 Days)
- QNRX 1.4M
- GLMD 41.9K
- Earning Date
- QNRX 03-12-2025
- GLMD 11-14-2024
- Dividend Yield
- QNRX N/A
- GLMD N/A
- EPS Growth
- QNRX N/A
- GLMD N/A
- EPS
- QNRX N/A
- GLMD N/A
- Revenue
- QNRX N/A
- GLMD N/A
- Revenue This Year
- QNRX N/A
- GLMD N/A
- Revenue Next Year
- QNRX N/A
- GLMD N/A
- P/E Ratio
- QNRX N/A
- GLMD N/A
- Revenue Growth
- QNRX N/A
- GLMD N/A
- 52 Week Low
- QNRX $0.43
- GLMD $2.56
- 52 Week High
- QNRX $6.18
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- QNRX 43.80
- GLMD 45.51
- Support Level
- QNRX $0.56
- GLMD $2.84
- Resistance Level
- QNRX $0.63
- GLMD $3.01
- Average True Range (ATR)
- QNRX 0.07
- GLMD 0.22
- MACD
- QNRX -0.00
- GLMD -0.02
- Stochastic Oscillator
- QNRX 11.56
- GLMD 13.41
About QNRX Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol. Its product, aramchol, is a disease-modifying treatment for fatty liver disorders, including Non-Alcoholic Steato-hepatitis. Aramchol affects liver fat metabolism and has been shown in a Phase IIa clinical study to reduce liver fat content, as well as improve metabolic parameters associated with Nonalcoholic steatohepatitis.